Sphingolipids and atherosclerosis: a mechanistic connection? A therapeutic opportunity?
Tabas
Ira
I
D000217:Acyltransferases / Q000037:antagonists & inhibitors; D000818:Animals; D001057:Apolipoproteins E / Q000172:deficiency / Q000235:genetics; D001161:Arteriosclerosis / Q000378:metabolism* / Q000517:prevention & control; D004036:Diet, Atherogenic; D004353:Drug Evaluation, Preclinical; D005229:Fatty Acids, Monounsaturated / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy / Q000235:genetics; D008074:Lipoproteins / Q000097:blood; D008075:Lipoproteins, HDL / Q000097:blood; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D023421:Models, Animal; D051102:Serine C-Palmitoyltransferase; D013045:Species Specificity; D013107:Sphingolipids / Q000378:metabolism*; D013108:Sphingomyelin Phosphodiesterase / Q000378:metabolism
D001057:Apolipoproteins E; D005229:Fatty Acids, Monounsaturated; D008074:Lipoproteins; D008075:Lipoproteins, HDL; D013107:Sphingolipids; D000217:Acyltransferases; C495089:SPTLC2 protein, human; D051102:Serine C-Palmitoyltransferase; C495088:Sptlc1 protein, mouse; D013108:Sphingomyelin Phosphodiesterase; C001996:thermozymocidin